Amphetamine Patent Expiration
Amphetamine was first introduced by Neos Therapeutics
Amphetamine Patents
Given below is the list of patents protecting Amphetamine, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Adzenys Er | US8709491 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles | Jun 28, 2032 | Neos Theraps Inc |
| Adzenys Er | US9017731 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles | Jun 28, 2032 | Neos Theraps Inc |
| Adzenys Er | US9265737 | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles | Jun 28, 2032 | Neos Theraps Inc |
| Adzenys Xr-odt | US8709491 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles | Jun 28, 2032 | Neos Theraps |
| Adzenys Xr-odt | US9017731 | Composition comprising a mixture of dextro- and levo-amphetamines complexed with ion-exchange resin particles to form drug resin particles | Jun 28, 2032 | Neos Theraps |
| Adzenys Xr-odt | US9265737 | Pharmaceutical composition comprising amphetamines complexed with ion-exchange resin particles | Jun 28, 2032 | Neos Theraps |
| Adzenys Xr-odt | US9839619 | Method for treating ADD or ADHD comprising administering amphetamine complexed with ion-exchange resin particles | Jun 28, 2032 | Neos Theraps |
| Adzenys Xr-odt | US8840924 | Compositions and methods of making rapidly dissolving ionically masked formulations |
Apr 09, 2026
(Expired) | Neos Theraps |
Amphetamine's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List
Clinical Trials
Recent Clinical Trials on Amphetamine:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Ketamine for Methamphetamine Use Disorder | University of Texas Southwestern Medical Center | NA |
ACTIVE NOT RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Psilocybin for Methamphetamine Use Disorder | Peter Hendricks | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| Randomized Controlled Trial of Tirzepatide for Methamphetamine Use Disorder | University of Texas Southwestern Medical Center | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |
| MDMA-Assisted Therapy for Veterans With Moderate to Severe Post Traumatic Stress Disorder | Stephen Robert Marder | NA |
RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Transdermal Rotigotine as Adjunct to Behavioral Therapy for Cocaine Use Disorder | Virginia Commonwealth University | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| MDMA-assisted Massed Prolonged Exposure for PTSD | Healing Breakthrough | NA |
ACTIVE NOT RECRUITING
(Aug 1, 2026)
| PHASE3 |
| Ketamine-Assisted Recovery for Methamphetamine Use Disorder & HIV | Nicky Mehtani, MD, MPH | NA |
COMPLETED
(Aug 1, 2026)
| PHASE2 |
| Methamphetamine Isomer Pharmacology in Humans | University of Wisconsin, Madison | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE1 |
| Methylphenidate and Response to Alcohol Cues | University of Florida | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder | University of Texas Southwestern Medical Center | NA |
ENROLLING BY INVITATION
(Aug 1, 2026)
| PHASE2 |
| Psilocybin Therapy for Methamphetamine Use Disorder and HIV | Nicky Mehtani, MD, MPH | NA |
NOT YET RECRUITING
(Aug 1, 2026)
| PHASE2 |
| Preliminary Effectiveness of Individual and Group MDMA-assisted Therapy for Israeli Veterans With PTSD and Moral Injury. | HaEmek Medical Center, Israel | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| MDMA Plus Exposure Therapy for PTSD | Emory University | NA |
ENROLLING BY INVITATION
(Jul 1, 2026)
| PHASE2 |
| Tolerability of MDMA in Schizophrenia | Anya Bershad, MD, PhD | NA |
RECRUITING
(Jul 1, 2026)
| PHASE1, PHASE2 |
| Mirtazapine for the Treatment of Methamphetamine Use in Opioid Use Disorder Patients Receiving Medication Assisted Treatment | Washington State University | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| A Single-Dose Study to Evaluate Safety and Efficacy of CS-1103 in Participants Receiving a Single Dose of Methamphetamine | Clear Scientific, Inc. | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Decreasing Risk of Psychosis by Sulforaphane (DROPS Trial) | Shanghai Jiao Tong University School of Medicine | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Naltrexone for Overdose Prevention | University of California, San Francisco | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2, PHASE3 |
| Glutide for Ending Methamphetamine | San Francisco Department of Public Health | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT Study | Kirby Institute | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Effects of Stimulant Medications in PTSD | University of Chicago | NA |
NOT YET RECRUITING
(Jun 1, 2026)
| PHASE1 |
| Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder | University of Wisconsin, Madison | NA |
TERMINATED
(May 1, 2026)
| PHASE1 |
| Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder | Parnassia Addiction Research Centre | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| Comparative Acute Effects of R-MDMA and S-MDMA in Healthy Participants | University Hospital, Basel, Switzerland | NA |
COMPLETED
(May 1, 2026)
| PHASE1 |
| MDMA-Assisted Massed Exposure Therapy for PTSD | Emory University | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| A Study to Evaluate the Abuse Potential of EB-1020 Immediate-Release in Healthy Recreational Stimulant Users | Otsuka Pharmaceutical Development & Commercialization, Inc. | NA |
COMPLETED
(Apr 1, 2026)
| PHASE1 |
| Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder | Portland VA Research Foundation, Inc | NA |
ACTIVE NOT RECRUITING
(Apr 1, 2026)
| PHASE1, PHASE2 |
| MDMA for Co-occurring PTSD and OUD After Childbirth | University of New Mexico | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |
| Effects of Ketone Supplement and Alcohol on Brain Metabolism | University of Pennsylvania | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2, PHASE3 |